Discover cutting-edge insights from recent clinical trials presented at the 2025 ACC. Hear about the WARRIOR trial's impact on non-obstructive coronary artery disease, and explore findings from PROTECT TAVI regarding cerebral embolic protection. Dive into DAPATAVI, where SGLT2 inhibitors emerge as potential new standards following TAVI. Plus, learn how oral semaglutide is shifting the landscape of diabetes management and its effects on cardiovascular outcomes!
26:56
forum Ask episode
web_stories AI Snips
view_agenda Chapters
auto_awesome Transcript
info_circle Episode notes
question_answer ANECDOTE
PFA Conversion
John Mandrola attended the European Heart Rhythm meeting and debated PFA.
He admitted to being a PFA convert, having not performed thermal ablation in nine months.
question_answer ANECDOTE
Fast TAVI Procedure
Mandrola visited the University Medical Center Amsterdam and observed a 20-minute TAVI procedure.
The procedure was done with the patient awake and was faster than most AF ablations.
insights INSIGHT
WARRIOR Trial Limitations
The WARRIOR trial's pragmatic design led to contamination, as both groups received similar therapies.
This limited the trial's ability to determine the effectiveness of intensive medical therapy for INOCA.
Get the Snipd Podcast app to discover more snips from this episode
Trials from the 2025 American College of Cardiology scientific sessions, including the WARRIOR, PROTECT TAVI, DAPATAVI, and SOUL are reviewed by John Mandrola, MD
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I Thank you Comments
II WARRIOR Women’s IschemiA TRial to Reduce Events In Non-ObstRuctive CAD
Keep Fighting INOCA After Neutral WARRIOR Trial https://www.medscape.com/viewarticle/keep-fighting-inoca-after-neutral-warrior-trial-2025a10007uf
Instrumental Variables in Randomized Trials https://evidence.nejm.org/doi/10.1056/EVIDctw2400204
IV DAPATAVI
SGLT2 Inhibitors Progressing to New Standard After TAVI https://www.medscape.com/viewarticle/sglt2-inhibitors-progressing-new-standard-after-tavi-2025a100081y
Dapagliflozin in Patients Undergoing Transcatheter Aortic-Valve Implantation https://www.nejm.org/doi/full/10.1056/NEJMoa2500366
V SOUL Study of Oral Semaglutide and CV outcomes in Diabetes
Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabeteshttps://www.nejm.org/doi/full/10.1056/NEJMoa2501006
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
This Week in Cardiology